Multitarget TB drug could treat other diseases, evade resistance — ScienceDaily
source : http://www.sciencedaily.com/releases/2014/04/140417192006.htm
source : http://www.sciencedaily.com/releases/2014/04/140417192006.htm
source : http://www.sciencedaily.com/releases/2014/02/140210161234.htm
source : http://www.sciencedaily.com/releases/2014/02/140207083927.htm
source : http://www.sciencedaily.com/releases/2013/12/131220121046.htm
The study, published in the journal Nature Immunology and led by Professor Uwe Vinkemeier in the University’s School of Life Sciences, centred on STAT1, a protein that can bind DNA and hence plays a vital role in regulating genes in the body. STAT1 responds to interferon signals, hormone-like molecules which control communication between cells to trigger defensive action by the body’s immune system when pathogens such as bacteria, viruses, or parasites are detected. …
"The research of the circulating tumour cells (CTC) is of utmost importance, because nowadays there is no reliable marker of both cancer-specific or overall survival in castration-resistant prostate cancer (CRPC) patients," explained the lead author of the study, Dr. …
Writing in the October 7 Early Edition of PNAS, Lars Eckmann, MD, professor of medicine, and colleagues describe creating more than 650 new compounds by slightly altering structural elements of metronidazole and other 5-nitromidazoles (5-NI), a half-century-old class of antimicrobial drugs used to combat everything from an ulcer-causing stomach bacterium to a gut-churning protozoan found in contaminated water. "The basic building blocks of 5-NI drugs are the same for all. We decorated around them, adding extra molecular pieces to change their shapes and sizes," said Eckmann, who published the paper with colleagues at UC San Diego, The Scripps Research Institute and the Queensland Institute of Medical Research in Australia…